Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by gojotv!on Jun 15, 2021 1:23pm
236 Views
Post# 33389157

Tha Clarus Kerfuffle...

Tha Clarus Kerfuffle...When Atkinson at Clarus lowered his price target to $1.25, he believed that SZLS had abandoned the "employer group testing" market. Tripp quickly corrected that, but many didn't pause to listen. The ensuing weeks-long short attack left a huge gap between current share price and actual value.
Which creates an opportunity now... It's clear that StageZero is very actively pursuing the employer market, and has other healthcare interests, such as; StayWell in Florida bringing patients into the fold.
With Aristotle's unparallelled accuracy as a multi-cancer diagnostic test,(better than Grail's multi-billion dollar "Galieri" test) it won't be long before that market has been addressed by SZLS.
It's such a brilliant business plan that even Grail are doing the same.
So, Atkinson's $1.25 price target probably needs an upward revision.
But don't expect it until after the next financials.
Investment analysts' main strength is their reputation, and no one wants to admit they overreacted, IMHO.

<< Previous
Bullboard Posts
Next >>